EE424 Cost-Utility and Budget Impact Analyses of Tumor Necrosis Factor Inhibitor Biologics and Biosimilars Versus Rituximab in Thai Patients with Active Rheumatoid Arthritis
Dec 1, 2023, 00:00 AM
10.1016/j.jval.2023.09.690
https://www.valueinhealthjournal.com/article/S1098-3015(23)03820-2/fulltext
Section Title :
Section Order :
10175
First Page :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(23)03820-2&doi=10.1016/j.jval.2023.09.690